These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8330470)

  • 21. Torsemide: a new loop diuretic.
    Fowler SF; Murray KM
    Am J Health Syst Pharm; 1995 Aug; 52(16):1771-80; quiz 1814-5. PubMed ID: 8528833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with hepatic cirrhosis.
    Hayton WL; Kneer J; Blouin RA; Stoeckel K
    Antimicrob Agents Chemother; 1990 Jul; 34(7):1318-22. PubMed ID: 2386364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical pharmacokinetics and pharmacodynamics of torasemide.
    Knauf H; Mutschler E
    Clin Pharmacokinet; 1998 Jan; 34(1):1-24. PubMed ID: 9474471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease.
    Vasavada N; Saha C; Agarwal R
    Kidney Int; 2003 Aug; 64(2):632-40. PubMed ID: 12846760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of torasemide and its metabolites in healthy controls and in chronic renal failure.
    Spahn H; Knauf H; Mutschler E
    Eur J Clin Pharmacol; 1990; 39(4):345-8. PubMed ID: 2076715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of oral administration of furosemide and torsemide in healthy dogs.
    Hori Y; Takusagawa F; Ikadai H; Uechi M; Hoshi F; Higuchi S
    Am J Vet Res; 2007 Oct; 68(10):1058-63. PubMed ID: 17916010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and bioavailability of piretanide in healthy volunteers following intramuscular administration.
    Trenk D; Wagner F; Jähnchen E; Spahn H; Mutschler E
    Arzneimittelforschung; 1987 Dec; 37(12):1382-5. PubMed ID: 3449067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and torsemide in patients with heart failure.
    Gottlieb SS; Khatta M; Wentworth D; Roffman D; Fisher ML; Kramer WG
    Am J Med; 1998 Jun; 104(6):533-8. PubMed ID: 9674715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sodium and Fluid Excretion With Torsemide in Healthy Subjects is Limited by the Short Duration of Diuretic Action.
    Shah S; Pitt B; Brater DC; Feig PU; Shen W; Khwaja FS; Wilcox CS
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28982672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of ascites on the pharmacokinetics of piretanide in cirrhotic patients.
    Shepherd AN; Bouchier IA
    Eur J Clin Pharmacol; 1985; 28(5):581-3. PubMed ID: 4043200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure.
    Murray MD; Deer MM; Ferguson JA; Dexter PR; Bennett SJ; Perkins SM; Smith FE; Lane KA; Adams LD; Tierney WM; Brater DC
    Am J Med; 2001 Nov; 111(7):513-20. PubMed ID: 11705426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal responses and pharmacokinetics of piretanide in humans: effect of route of administration, state of hydration and probenecid pretreatment.
    Noormohamed FH; McNabb WR; Dixey JJ; Lant AF
    J Pharmacol Exp Ther; 1990 Sep; 254(3):992-9. PubMed ID: 2395126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A bioavailability/bioequivalence and pharmacokinetic study of two oral doses of torasemide (5 and 10 mg): prolonged-release versus the conventional formulation.
    Barbanoj MJ; Ballester MR; Antonijoan RM; Puntes M; Gropper S; Santos B; Albet C; Guglietta A
    Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):469-77. PubMed ID: 19673928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Torsemide Investigators Group.
    Patterson JH; Adams KF; Applefeld MM; Corder CN; Masse BR
    Pharmacotherapy; 1994; 14(5):514-21. PubMed ID: 7997385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose-response study of intravenous torsemide in congestive heart failure.
    Hariman RJ; Bremner S; Louie EK; Rogers WJ; Kostis JB; Nocero MA; Jones JP
    Am Heart J; 1994 Aug; 128(2):352-7. PubMed ID: 8037103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of torasemide and its metabolites in end-stage renal disease.
    Krämer BK; Schwab A; Braun N; Strutz F; Müller GA; Risler T
    Eur J Clin Pharmacol; 1994; 47(2):157-9. PubMed ID: 7859803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose-independent pharmacokinetics of torasemide after intravenous and oral administration to rats.
    Lee DY; Kim JY; Kim YC; Kwon JW; Kim WB; Lee MG
    Biopharm Drug Dispos; 2005 Jul; 26(5):173-82. PubMed ID: 15841492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous torasemide in rats.
    Lee AK; Kim EJ; Lee MG
    Res Commun Mol Pathol Pharmacol; 2003; 113-114():193-200. PubMed ID: 15686118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical pharmacology of torasemide, a new loop diuretic.
    Brater DC; Leinfelder J; Anderson SA
    Clin Pharmacol Ther; 1987 Aug; 42(2):187-92. PubMed ID: 3608350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comprehensive review of the loop diuretics: should furosemide be first line?
    Wargo KA; Banta WM
    Ann Pharmacother; 2009 Nov; 43(11):1836-47. PubMed ID: 19843838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.